{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T14:33:44Z","timestamp":1783348424149,"version":"3.54.6"},"reference-count":49,"publisher":"American Society of Hematology","issue":"26","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2019,12,26]]},"abstract":"<jats:p>The authors describe recurrent novel insertion\/deletion mutations in the JH2 domain of JAK2 occurring in patients with eosinophilia as a prominent feature of their myeloproliferative neoplasms. Remarkably, 2 of the patients with a specific mutation (Leu583-Ala586DelInsSer) meet the criteria for both chronic eosinophilic leukemia and polycythemia vera, suggesting that this may be a distinct overlap syndrome.<\/jats:p>","DOI":"10.1182\/blood.2019001385","type":"journal-article","created":{"date-parts":[[2019,10,14]],"date-time":"2019-10-14T15:00:46Z","timestamp":1571065246000},"page":"2388-2398","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":37,"title":["JAK2\n          ex13InDel drives oncogenic transformation and is associated with chronic eosinophilic leukemia and polycythemia vera"],"prefix":"10.1182","volume":"134","author":[{"given":"Ami B.","family":"Patel","sequence":"first","affiliation":[{"name":"Division of Hematology and Hematologic Malignancies, The University of Utah, Salt Lake City, UT;"},{"name":"Huntsman Cancer Institute, The University of Utah, Salt Lake City, UT;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0359-5399","authenticated-orcid":false,"given":"Anca","family":"Franzini","sequence":"additional","affiliation":[{"name":"Huntsman Cancer Institute, The University of Utah, Salt Lake City, UT;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilie","family":"Leroy","sequence":"additional","affiliation":[{"name":"Ludwig Cancer Research Brussels and de Duve Institute, Universit\u00e9 Catholique de Louvain, Brussels, Belgium;"},{"name":"WELBIO (Walloon Excellence in Life Sciences and Biotechnology), Brussels, Belgium;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soo Jin","family":"Kim","sequence":"additional","affiliation":[{"name":"Huntsman Cancer Institute, The University of Utah, Salt Lake City, UT;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony D.","family":"Pomicter","sequence":"additional","affiliation":[{"name":"Huntsman Cancer Institute, The University of Utah, Salt Lake City, UT;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lidvine","family":"Genet","sequence":"additional","affiliation":[{"name":"Ludwig Cancer Research Brussels and de Duve Institute, Universit\u00e9 Catholique de Louvain, Brussels, Belgium;"},{"name":"WELBIO (Walloon Excellence in Life Sciences and Biotechnology), Brussels, Belgium;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6798-5567","authenticated-orcid":false,"given":"Michael","family":"Xiao","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, The University of Utah School of Medicine, Salt Lake City, UT;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongqing","family":"Yan","sequence":"additional","affiliation":[{"name":"Huntsman Cancer Institute, The University of Utah, Salt Lake City, UT;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan M.","family":"Ahmann","sequence":"additional","affiliation":[{"name":"Huntsman Cancer Institute, The University of Utah, Salt Lake City, UT;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Archana M.","family":"Agarwal","sequence":"additional","affiliation":[{"name":"Division of Clinical Pathology, Department of Pathology, University of Utah School of Medicine, Salt Lake City, UT;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phillip","family":"Clair","sequence":"additional","affiliation":[{"name":"Division of Hematology and Hematologic Malignancies, The University of Utah, Salt Lake City, UT;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juanah","family":"Addada","sequence":"additional","affiliation":[{"name":"Department of Haematology, Royal Derby Hospital, Derby, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Lambert","sequence":"additional","affiliation":[{"name":"Department of Clinical Haematology, University College London Hospitals, London, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Salmon","sequence":"additional","affiliation":[{"name":"Wessex Regional Genetics Laboratory, Salisbury NHS Foundation Trust, Salisbury, United Kingdom;"},{"name":"Faculty of Medicine, University of Southampton, Southampton, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald J.","family":"Gleich","sequence":"additional","affiliation":[{"name":"Department of Dermatology and"},{"name":"Department of Medicine, The University of Utah, Salt Lake City, UT; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas C. P.","family":"Cross","sequence":"additional","affiliation":[{"name":"Wessex Regional Genetics Laboratory, Salisbury NHS Foundation Trust, Salisbury, United Kingdom;"},{"name":"Faculty of Medicine, University of Southampton, Southampton, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan N.","family":"Constantinescu","sequence":"additional","affiliation":[{"name":"Ludwig Cancer Research Brussels and de Duve Institute, Universit\u00e9 Catholique de Louvain, Brussels, Belgium;"},{"name":"WELBIO (Walloon Excellence in Life Sciences and Biotechnology), Brussels, Belgium;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"O\u2019Hare","sequence":"additional","affiliation":[{"name":"Division of Hematology and Hematologic Malignancies, The University of Utah, Salt Lake City, UT;"},{"name":"Huntsman Cancer Institute, The University of Utah, Salt Lake City, UT;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8019-2940","authenticated-orcid":false,"given":"Josef T.","family":"Prchal","sequence":"additional","affiliation":[{"name":"Division of Hematology and Hematologic Malignancies, The University of Utah, Salt Lake City, UT;"},{"name":"Veteran Administration Medical Center, Salt Lake City, UT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael W.","family":"Deininger","sequence":"additional","affiliation":[{"name":"Division of Hematology and Hematologic Malignancies, The University of Utah, Salt Lake City, UT;"},{"name":"Huntsman Cancer Institute, The University of Utah, Salt Lake City, UT;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"8","key":"2019122611531513400_B1","doi-asserted-by":"crossref","first-page":"2862","DOI":"10.1182\/blood-2005-04-1515","article-title":"The Jak2V617F mutation, PRV-1 overexpression, and EEC formation define a similar cohort of MPD patients","volume":"106","author":"Goerttler","year":"2005","journal-title":"Blood"},{"issue":"9464","key":"2019122611531513400_B2","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(05)71142-9","article-title":"Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders","volume":"365","author":"Baxter","year":"2005","journal-title":"Lancet"},{"issue":"12","key":"2019122611531513400_B3","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.3324\/haematol.11643","article-title":"The frequency of JAK2 exon 12 mutations in idiopathic erythrocytosis patients with low serum erythropoietin levels","volume":"92","author":"Percy","year":"2007","journal-title":"Haematologica"},{"issue":"8","key":"2019122611531513400_B4","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1002\/ajh.22063","article-title":"The JAK2 exon 12 mutations: a comprehensive review","volume":"86","author":"Scott","year":"2011","journal-title":"Am J Hematol"},{"issue":"5","key":"2019122611531513400_B5","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1056\/NEJMoa065202","article-title":"JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis","volume":"356","author":"Scott","year":"2007","journal-title":"N Engl J Med"},{"issue":"11","key":"2019122611531513400_B6","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1002\/cncr.31986","article-title":"Janus kinase 2 variants associated with the transformation of myeloproliferative neoplasms into acute myeloid leukemia","volume":"125","author":"Benton","year":"2019","journal-title":"Cancer"},{"issue":"18","key":"2019122611531513400_B7","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1182\/blood-2016-04-711283","article-title":"Coexistence of gain-of-function JAK2 germ line mutations with JAK2V617F in polycythemia vera","volume":"128","author":"Lanikova","year":"2016","journal-title":"Blood"},{"issue":"10","key":"2019122611531513400_B8","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1182\/blood-2016-02-698951","article-title":"Cooperation of germ line JAK2 mutations E846D and R1063H in hereditary erythrocytosis with megakaryocytic atypia","volume":"128","author":"Kapralova","year":"2016","journal-title":"Blood"},{"issue":"9","key":"2019122611531513400_B9","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1182\/blood-2013-05-504555","article-title":"Germ-line JAK2 mutations in the kinase domain are responsible for hereditary thrombocytosis and are resistant to JAK2 and HSP90 inhibitors","volume":"123","author":"Marty","year":"2014","journal-title":"Blood"},{"issue":"7","key":"2019122611531513400_B10","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1182\/blood-2012-12-473777","article-title":"A novel activating, germline JAK2 mutation, JAK2R564Q, causes familial essential thrombocytosis","volume":"123","author":"Etheridge","year":"2014","journal-title":"Blood"},{"issue":"1","key":"2019122611531513400_B11","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1002\/ajh.23614","article-title":"A novel germline JAK2 mutation in familial myeloproliferative neoplasms","volume":"89","author":"Rumi","year":"2014","journal-title":"Am J Hematol"},{"issue":"52","key":"2019122611531513400_B12","doi-asserted-by":"crossref","first-page":"18962","DOI":"10.1073\/pnas.0509714102","article-title":"Expression of a homodimeric type I cytokine receptor is required for JAK2V617F-mediated transformation","volume":"102","author":"Lu","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"issue":"5","key":"2019122611531513400_B13","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1002\/stem.160301","article-title":"Mechanism of activation of the GM-CSF, IL-3, and IL-5 family of receptors","volume":"16","author":"Guthridge","year":"1998","journal-title":"Stem Cells"},{"issue":"11","key":"2019122611531513400_B14","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1042\/BCJ20160085","article-title":"Uncoupling JAK2 V617F activation from cytokine-induced signalling by modulation of JH2 \u03b1C helix","volume":"473","author":"Leroy","year":"2016","journal-title":"Biochem J"},{"issue":"9","key":"2019122611531513400_B15","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1038\/nsmb.2099","article-title":"The pseudokinase domain of JAK2 is a dual-specificity protein kinase that negatively regulates cytokine signaling","volume":"18","author":"Ungureanu","year":"2011","journal-title":"Nat Struct Mol Biol"},{"issue":"24","key":"2019122611531513400_B16","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1056\/NEJM197406132902419","article-title":"Letter: Bone-marrow responses in polycythemia vera","volume":"290","author":"Prchal","year":"1974","journal-title":"N Engl J Med"},{"issue":"20","key":"2019122611531513400_B17","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"issue":"9","key":"2019122611531513400_B18","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1002\/ajh.24075","article-title":"KIT D816V and JAK2 V617F mutations are seen recurrently in hypereosinophilia of unknown significance","volume":"90","author":"Schwaab","year":"2015","journal-title":"Am J Hematol"},{"issue":"6","key":"2019122611531513400_B19","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1182\/blood-2016-10-695973","article-title":"Myeloid neoplasms with eosinophilia","volume":"129","author":"Reiter","year":"2017","journal-title":"Blood"},{"key":"2019122611531513400_B20","first-page":"290","volume-title":"Assay Guidance Manual","author":"Riss","year":"2004"},{"issue":"12","key":"2019122611531513400_B21","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.1038\/leu.2015.249","article-title":"Presence of polyclonal hematopoiesis in females with Ph-negative myeloproliferative neoplasms","volume":"29","author":"Swierczek","year":"2015","journal-title":"Leukemia"},{"issue":"13","key":"2019122611531513400_B22","doi-asserted-by":"crossref","first-page":"e100","DOI":"10.1182\/blood-2011-11-390351","article-title":"Methylation of AR locus does not always reflect X chromosome inactivation state","volume":"119","author":"Swierczek","year":"2012","journal-title":"Blood"},{"issue":"8","key":"2019122611531513400_B23","doi-asserted-by":"crossref","first-page":"3186","DOI":"10.1182\/blood-2008-03-143925","article-title":"Hematopoiesis is not clonal in healthy elderly women","volume":"112","author":"Swierczek","year":"2008","journal-title":"Blood"},{"issue":"1","key":"2019122611531513400_B24","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.exphem.2006.11.012","article-title":"Polycythemia vera is not initiated by JAK2V617F mutation","volume":"35","author":"Nussenzveig","year":"2007","journal-title":"Exp Hematol"},{"issue":"10","key":"2019122611531513400_B25","doi-asserted-by":"crossref","first-page":"3793","DOI":"10.1182\/blood-2003-03-0885","article-title":"Clonal hematopoiesis in familial polycythemia vera suggests the involvement of multiple mutational events in the early pathogenesis of the disease","volume":"102","author":"Kralovics","year":"2003","journal-title":"Blood"},{"issue":"6","key":"2019122611531513400_B26","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/nprot.2015.053","article-title":"The Phyre2 web portal for protein modeling, prediction and analysis","volume":"10","author":"Kelley","year":"2015","journal-title":"Nat Protoc"},{"issue":"8","key":"2019122611531513400_B27","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1038\/nsmb.2348","article-title":"Crystal structures of the JAK2 pseudokinase domain and the pathogenic mutant V617F","volume":"19","author":"Bandaranayake","year":"2012","journal-title":"Nat Struct Mol Biol"},{"issue":"9","key":"2019122611531513400_B28","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1038\/leu.2016.73","article-title":"Predictors of survival in WHO-defined hypereosinophilic syndrome and idiopathic hypereosinophilia and the role of next-generation sequencing","volume":"30","author":"Pardanani","year":"2016","journal-title":"Leukemia"},{"issue":"8","key":"2019122611531513400_B29","doi-asserted-by":"crossref","first-page":"3294","DOI":"10.1182\/blood-2002-07-2287","article-title":"Discrimination of polycythemias and thrombocytoses by novel, simple, accurate clonality assays and comparison with PRV-1 expression and BFU-E response to erythropoietin","volume":"101","author":"Liu","year":"2003","journal-title":"Blood"},{"issue":"3","key":"2019122611531513400_B30","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0301-472X(01)00789-5","article-title":"Acquired uniparental disomy of chromosome 9p is a frequent stem cell defect in polycythemia vera","volume":"30","author":"Kralovics","year":"2002","journal-title":"Exp Hematol"},{"issue":"20","key":"2019122611531513400_B31","doi-asserted-by":"crossref","first-page":"3139","DOI":"10.1182\/blood-2013-06-510222","article-title":"JAK2V617F homozygosity drives a phenotypic switch in myeloproliferative neoplasms, but is insufficient to sustain disease","volume":"123","author":"Li","year":"2014","journal-title":"Blood"},{"issue":"5","key":"2019122611531513400_B32","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1182\/blood-2006-09-018655","article-title":"X-linked clonality testing: interpretation and limitations","volume":"110","author":"Chen","year":"2007","journal-title":"Blood"},{"issue":"4","key":"2019122611531513400_B33","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1182\/blood-2005-11-009605","article-title":"Acquisition of the V617F mutation of JAK2 is a late genetic event in a subset of patients with myeloproliferative disorders","volume":"108","author":"Kralovics","year":"2006","journal-title":"Blood"},{"issue":"10","key":"2019122611531513400_B34","doi-asserted-by":"crossref","first-page":"4139","DOI":"10.1182\/blood-2005-09-3900","article-title":"X-inactivation-based clonality analysis and quantitative JAK2V617F assessment reveal a strong association between clonality and JAK2V617F in PV but not ET\/MMM, and identifies a subset of JAK2V617F-negative ET and MMM patients with clonal hematopoiesis","volume":"107","author":"Levine","year":"2006","journal-title":"Blood"},{"issue":"7","key":"2019122611531513400_B35","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1038\/nsmb.2849","article-title":"Molecular basis for pseudokinase-dependent autoinhibition of JAK2 tyrosine kinase","volume":"21","author":"Shan","year":"2014","journal-title":"Nat Struct Mol Biol"},{"issue":"26","key":"2019122611531513400_B36","doi-asserted-by":"crossref","first-page":"4714","DOI":"10.2174\/1381612811319260005","article-title":"Rational approaches towards lead optimization of kinase inhibitors: the issue of specificity","volume":"19","author":"Badrinarayan","year":"2013","journal-title":"Curr Pharm Des"},{"key":"2019122611531513400_B37","doi-asserted-by":"crossref","first-page":"172","DOI":"10.3389\/fmicb.2014.00172","article-title":"Recombinant protein expression in Escherichia coli: advances and challenges","volume":"5","author":"Rosano","year":"2014","journal-title":"Front Microbiol"},{"issue":"1","key":"2019122611531513400_B38","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1182\/asheducation-2005.1.195","article-title":"A unique activating mutation in JAK2 (V617F) is at the origin of polycythemia vera and allows a new classification of myeloproliferative diseases","volume":"2005","author":"Vainchenker","year":"2005","journal-title":"Hematology (Am Soc Hematol Educ Program)"},{"issue":"1-2","key":"2019122611531513400_B39","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/0165-2478(94)00223-E","article-title":"Synergism of IL-3, IL-5, and GM-CSF on eosinophil differentiation and its application for an assay of murine IL-5 as an eosinophil differentiation factor","volume":"45","author":"Takamoto","year":"1995","journal-title":"Immunol Lett"},{"issue":"1","key":"2019122611531513400_B40","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1038\/s41467-017-02633-7","article-title":"A dual role for the N-terminal domain of the IL-3 receptor in cell signalling","volume":"9","author":"Broughton","year":"2018","journal-title":"Nat Commun"},{"issue":"48","key":"2019122611531513400_B41","doi-asserted-by":"crossref","first-page":"29022","DOI":"10.1074\/jbc.M115.670224","article-title":"Distinct acute lymphoblastic leukemia (ALL)-associated Janus kinase 3 (JAK3) mutants exhibit different cytokine-receptor requirements and JAK inhibitor specificities","volume":"290","author":"Losdyck","year":"2015","journal-title":"J Biol Chem"},{"issue":"3","key":"2019122611531513400_B42","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1006\/bbrc.2001.4824","article-title":"Critical sites for the interaction between IL-2Rgamma and JAK3 and the following signaling","volume":"283","author":"Tang","year":"2001","journal-title":"Biochem Biophys Res Commun"},{"issue":"40","key":"2019122611531513400_B43","doi-asserted-by":"crossref","first-page":"37451","DOI":"10.1074\/jbc.M106135200","article-title":"Mapping of a region within the N terminus of Jak1 involved in cytokine receptor interaction","volume":"276","author":"Haan","year":"2001","journal-title":"J Biol Chem"},{"issue":"22","key":"2019122611531513400_B44","doi-asserted-by":"crossref","first-page":"16651","DOI":"10.1074\/jbc.M109.071191","article-title":"Activation of JAK2-V617F by components of heterodimeric cytokine receptors","volume":"285","author":"Pradhan","year":"2010","journal-title":"J Biol Chem"},{"issue":"suppl 1","key":"2019122611531513400_B45","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1159\/000237712","article-title":"The activation of the JAK2\/STAT5 pathway is commonly involved in signaling through the human IL-5 receptor","volume":"114","author":"Ogata","year":"1997","journal-title":"Int Arch Allergy Immunol"},{"issue":"5","key":"2019122611531513400_B46","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1182\/blood.V81.5.1193.1193","article-title":"Cooperative effects of interleukin-3 (IL-3), IL-5, and granulocyte-macrophage colony-stimulating factor: a new myeloid cell line inducible to eosinophils","volume":"81","author":"Paul","year":"1993","journal-title":"Blood"},{"issue":"6","key":"2019122611531513400_B47","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1002\/j.1460-2075.1995.tb07100.x","article-title":"Interleukin-3, granulocyte-macrophage colony stimulating factor and interleukin-5 transduce signals through two STAT5 homologs","volume":"14","author":"Mui","year":"1995","journal-title":"EMBO J"},{"issue":"7","key":"2019122611531513400_B48","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1002\/j.1460-2075.1995.tb07126.x","article-title":"Interleukin-3 signals through multiple isoforms of Stat5","volume":"14","author":"Azam","year":"1995","journal-title":"EMBO J"},{"issue":"5","key":"2019122611531513400_B49","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1056\/NEJMoa1409002","article-title":"Ruxolitinib versus standard therapy for the treatment of polycythemia vera","volume":"372","author":"Vannucchi","year":"2015","journal-title":"N Engl J Med"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/134\/26\/2388\/1549680\/bloodbld2019001385.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/134\/26\/2388\/1549680\/bloodbld2019001385.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,12,26]],"date-time":"2019-12-26T11:53:42Z","timestamp":1577361222000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/134\/26\/2388\/381160\/JAK2ex13InDel-drives-oncogenic-transformation-and"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,26]]},"references-count":49,"journal-issue":{"issue":"26","published-print":{"date-parts":[[2019,12,26]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2019001385","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,26]]}}}